您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 欧洲共同体药房
产地国家: 欧洲共同体国家
所属类别: 妇科药物->子宫内膜异位
处方药:处方药
包装规格: 2毫克/片 28片/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
拜耳
生产厂家英文名:
Bayer Vital GmbH Geschäftsbereich Pharma
该药品相关信息网址1:
http://eurekasalud.es/prospecto-visanne+comp.+recub.+1%2F2+mg-65746
该药品相关信息网址2:
http://visanne.com/en/auth/prescribing-essentials/quick-visanne-facts/
原产地英文商品名:
VISANNE 2mg/tab 28tabs/box
原产地英文药品名:
DIENOGEST
中文参考商品译名:
VISANNE 2毫克/片 28片/盒
中文参考药品译名:
地诺孕素
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Endometriosis
临床试验期:
完成
中文适应病症参考翻译1:
子宫内膜异位症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201233122193729.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Visanne处方资料(仅供参考)

Visanne(Dienogest)-治疗子宫内膜异位新药获准上市
    拜耳先灵制药公司已完成了治疗子宫内膜异位症的新药Visanne在欧洲的审批程序。Visanne是每日一次的口服片剂,含地诺孕素2毫克用于治疗子宫内膜异位症。

  该公司称,一项研究计划表明,Visanne减轻子宫内膜异位症疼痛,减少子宫内膜异位症病灶并有良好的安全性和耐受性。计划于2010年第二季度开始将产品的推向市场。

  此外,Visanne已被证明是有效的GnRH类似物减少子宫内膜异位症疼痛优于安慰剂。缓解疼痛持续时间长(临床研究显示持续15个月),包括痛经,疼痛,经前痛,弥漫性盆腔疼痛和性交疼痛。

What is Visanne®?
Visanne contains 2 mg dienogest and is indicated for the treatment of endometriosis
Dienogest is a progestin that combines the properties of both 19-nortestosterone derivatives and progesterone derivatives

What makes Visanne® an excellent treatment option for endometriosis?
Visanne® effectively reduces both the painful symptoms of endometriosis and also underlying endometriotic lesions. It offers equivalent efficacy to gonadotropin-releasing hormone (GnRH) agonists but has a more favorable side-effect profile.
Visanne® is not associated with clinically relevant androgenic or hypoestrogenic effects associated with other agents such as danazol and GnRH agonists, respectively.
Dienogest is associated with moderate inhibition of gonadotropin secretion, which, when given continuously, leads to a hypoestrogenic environment and initial decidualisation of endometrial tissue, followed by atrophy of endometriotic lesions.
In addition to its effects on gonadotropin secretion, dienogest also directly inhibits proliferation of endometrium-like tissue.

How does Visanne® work?
Visanne reduces endometrial lesions through both local and systemic biological mechanisms. The active ingredient in Visanne, dienogest, is associated with moderate inhibition of gonadotropin-releasing hormone secretion.
Disruption of this hormonal pathway leads to a decrease in the level of estradio Dienogest also demonstrates a direct inhibitory effect on the proliferation of endometrium-like tissue. Additionally, preclinical evidence indicates that dienogest also shows anti-angiogenic properties.

How should Visanne ® be administered?
Visanne® is administered orally as a once-daily tablet.
Visanne® treatment can start on any day of the menstrual cycle, and must be continuous regardless of vaginal bleeding. Hormonal contraception should be stopped before initiation of Visanne®.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201233122193729.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2012-4-1
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com